Omega Fund Management Increases Stake in Bicara Therapeutics to Nearly 29% of Portfolio
On May 15, 2026, Omega Fund Management disclosed a purchase of 187,500 shares of Bicara Therapeutics (BCAX) for $3.23 million in an SEC filing. The investment increased the fund's position to nearly 29% of its reportable assets as of March 31, 2026. BCAX stock has risen by approximately 50% over the past year.
Tickers: $BCAX